CHRISTOPHER RANDOLPH: Open Payments
NPI 1669455606 · ANNISTON, AL. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,021 in 52 payments from 13 companies in 2025. Trend: 2023 $1,128 · 2024 $641 · 2025 $1,021
Food & beverage: $1,021
| Company | Payments | Amount |
|---|---|---|
| Neurocrine BioSciences, Inc. | 9 | $283 |
| Otsuka America Pharmaceutical, Inc. | 7 | $161 |
| ABBVIE INC. | 13 | $137 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 6 | $127 |
| Alkermes, Inc. | 3 | $70 |
| Collegium Pharmaceutical, Inc. | 3 | $53 |
| Teva Pharmaceuticals USA, Inc. | 3 | $52 |
| Vertical Pharmaceuticals, LLC | 2 | $31 |
| Supernus Pharmaceuticals, Inc. | 2 | $31 |
| Corium, LLC | 1 | $21 |
Products named: INGREZZA, VRAYLAR, CAPLYTA, REXULTI, ABILIFY ASIMTUFII, ARISTADA, Jornay PM, AUSTEDO XR.
Industry payments across AL — which companies pay providers there.
